Combination comprising N-acetyl-L-cysteine and its use
AssigneeIasomai AB
InventorsTiziana Parasassi, Graziella Costa, Ewa Krasnowska, Eugenia Pittaluga
Life of this patent
Estimating the term…
Abstract
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
Claims10
A method of providing increased efficacy of N-acetyl-L-cysteine (NAC) in the treatment of diseases where glutathione is involved and/or in which thiol (—SH) reduction/oxidation (redox) switches play a role, or diseases in which the antiproliferative and pro-differentiating effect, antioxidant effect, or anti-inflammatory effect of NAC is utilized, the method comprising:
- administering to a patient being treated for a disease selected from the diseases where glutathione is involved and/or in which thiol (—SH) reduction/oxidation (redox) switches play a role, or diseases in which the antiproliferative and pro-differentiating effect, antioxidant effect, or anti-inflammatory effect of NAC is utilized, a combination consisting of one or more excipients and active agents consisting of:
- (i) NAC;
- (ii) selenium in the form of selenomethionine (SeMet);
- and
- (iii) melatonin (Mel)
- and/or physiologically acceptable salts thereof,
- wherein the combination is administered orally at a daily dosage weight ratio of NAC to SeMet to Mel of 12,500:1:50 to 37,500:1:66.67, or the combination is administered epicutaneously at a weight percent ratio of NAC to SeMet to Mel of 50:5:1 to 300:30:1.
A method of providing increased efficacy of N-acetyl-L-cysteine (NAC) in the treatment of diseases where glutathione is involved and/or in which thiol (—SH) reduction/oxidation (redox) switches play a role, wherein the diseases consist of one or more of:
- diseases causing suboptimal immune response and/or HIV/AIDS, cataracts, radiation poisoning, mal-nutritive states, arduous physical stress, trauma, burns, bipolar disorder, major depressive disorder, or schizophrenia the method comprising:
- administering to a patient being treated for a disease selected from the diseases where glutathione is involved and/or in which thiol (—SH) reduction/oxidation (redox) switches play a role, a combination consisting of one or more excipients and active agents consisting of:
- (i) NAC;
- (ii) selenium in the form of selenomethionine (SeMet);
- and
- (iii) melatonin (Mel)
- and/or physiologically acceptable salts thereof
- wherein the combination is administered orally at a daily dosage weight ratio of NAC to SeMet to Mel of 12,500:1:50 to 37,500:1:66.67, or the combination is administered epicutaneously at a weight percent ratio of NAC to SeMet to Mel of 50:5:1 to 300:30:1.
A method of providing increased efficacy of N-acetyl-L-cysteine (NAC) in the treatment of diseases in which the antioxidant effect or anti-inflammatory effect of NAC is utilized, the method comprising:
- administering to a patient being treated for diseases in which the antioxidant effect or anti-inflammatory effect of NAC is utilized, a combination consisting of one or more excipients and active agents consisting of:
- (i) NAC;
- (ii) selenium in the form of selenomethionine (SeMet);
- and
- (iii) melatonin (Mel)
- and/or physiologically acceptable salts thereof
- wherein the combination is administered orally at a daily dosage weight ratio of NAC to SeMet to Mel of 12,500:1:50 to 37,500:1:66.67, or the combination is administered epicutaneously at a weight percent ratio of NAC to SeMet to Mel of 50:5:1 to 300:30:1.
Dependencies are inferred from the claim text.